|

Liposomal Irinotecan+Tislelizumab+Capecitabine+Rradiotherapy Clinical Trials

1 actively recruiting trial

Also known as: New Neoadjuvant Treatment Approach

Pipeline

Phase 2: 1

Top Sponsors

  • Affiliated Cancer Hospital of Shantou University Medical College1

Indications

Other1 trial

Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.